Lombard Odier Asset Management Europe Ltd Acquires Shares of 1,690 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Lombard Odier Asset Management Europe Ltd purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,690 shares of the biopharmaceutical company’s stock, valued at approximately $1,776,000.

Other large investors also recently bought and sold shares of the company. West Paces Advisors Inc. increased its position in Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares during the last quarter. Stephens Consulting LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter worth $26,000. Sachetta LLC increased its position in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter worth $28,000. Finally, Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals in the second quarter worth $33,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on REGN shares. TD Cowen boosted their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. JPMorgan Chase & Co. boosted their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, September 16th. Royal Bank of Canada reiterated an “outperform” rating and set a $1,282.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 17th. Finally, Truist Financial reiterated a “buy” rating and set a $1,200.00 price objective (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,111.30.

Insider Activity at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. Insiders sold 9,270 shares of company stock worth $10,695,833 in the last three months. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Trading Down 4.6 %

Shares of NASDAQ:REGN opened at $1,091.98 on Tuesday. The business’s 50 day moving average price is $1,131.94 and its 200-day moving average price is $1,033.46. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The firm has a market capitalization of $120.32 billion, a price-to-earnings ratio of 32.26, a price-to-earnings-growth ratio of 3.93 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same period last year, the company earned $8.79 EPS. The company’s quarterly revenue was up 12.3% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.